Bernstein Harold 4

What Happened

• Harold Bernstein, President R&D & Chief Medical Officer at Maze Therapeutics, exercised 14,853 stock options and sold all 14,853 resulting shares on June 1, 2026. He paid $10.42 per share on exercise (total cost $154,768) and sold the shares in two blocks for total proceeds of $381,112 (13,253 shares at a weighted avg $25.57 for $338,940; 1,600 shares at a weighted avg $26.36 for $42,172). Net proceeds (sale proceeds minus exercise cost) were about $226,344. These sales were executed under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (period of report June 1, 2026).
• Exercise: 14,853 shares at $10.42 each — $154,768 total (code M).
• Sales: 13,253 shares at weighted avg $25.57 (sales ranged $25.16–$26.10) and 1,600 shares at weighted avg $26.36 (sales ranged $26.16–$26.53); total proceeds $381,112.
• A reported derivative disposition at $0 reflects the conversion/exercise of the option into shares.
• Footnote: Sales effected pursuant to a Rule 10b5-1 plan adopted Sept 29, 2025; weighted-average sale prices reported with ranges (per filing).
• Shares owned after the transactions: not specified in the provided filing.
• Filing timeliness: no late filing flag indicated.

Context

• This was effectively a cashless exercise followed by immediate open-market sales (common for option holders to cover exercise cost/taxes or monetize gains). The presence of a 10b5-1 plan means the sales were prearranged. The option vesting schedule noted in the filing: 1/4 vested Oct 3, 2023, with the remainder vesting monthly (1/48th) thereafter, subject to continued service.